Baird Maintains Outperform on Crinetics Pharmaceuticals, Raises Price Target to $62
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Brian Skorney maintains an Outperform rating on Crinetics Pharmaceuticals (NASDAQ:CRNX) and raises the price target from $52 to $62.
May 23, 2024 | 4:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baird analyst Brian Skorney has maintained an Outperform rating on Crinetics Pharmaceuticals and increased the price target from $52 to $62.
The increase in the price target from $52 to $62 by a reputable analyst suggests a positive outlook for Crinetics Pharmaceuticals, likely leading to a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100